Systematic meta-analysis of several AD patient CSF cytokine studies revealed heightened expression of TGF-β and MCP-1 in AD patients compared to controls, suggesting that these cytokines could be used as biomarkers for this disease (85). This evidence concerns the gene CCL2 and Alzheimer disease.